Special Issue

Molecular and Cellular Biology of Glioblastoma: 2nd Edition

Message from the Guest Editors

Glioblastoma remains the most aggressive among brain tumors, with a median survival of merely 14 to 16 months post-diagnosis, even with comprehensive treatment strategies encompassing surgery, chemotherapy, and radiotherapy. This recurring tumor displays an escalating resilience to TMZ treatment cycles, leading to the development of drug resistance—an overarching challenge that undermines efforts to improve patient outcomes.

While the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) was initially implicated in drug resistance within glioblastoma, recent studies have revealed that MGMT contributes to approximately 40% of recurrent glioblastoma cases.

However, the medical community still lacks a robust methodology or biomarker capable of predicting therapeutic response and anticipating the likelihood of tumor recurrence in glioblastoma cases. Therefore, overcoming the complexities of drug resistance, understanding intricate mechanisms, and pinpointing reliable biomarkers are pivotal areas where future research and medical efforts need to be directed to pave the way for more effective therapies and improved patient outcomes.

Guest Editors

Dr. Tsung-I Hsu

Ph.D. Program for Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan

Prof. Dr. Jian-Ying Chuang

Ph.D. Program for Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan

Deadline for manuscript submissions

closed (31 January 2024)



Life

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 6.0 Indexed in PubMed



mdpi.com/si/181714

Life
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/ life





Life

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)

